Rising Cancer Incidences is Driving Indian Peripheral Neuropathy Treatment Market

Indian peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.8% during the forecast period. Rising cancer incidences is one of the major factors driving the market growth. As per the World Health Organization (WHO), the number of new cancer incidences in India was nearly 1.1 million in 2018. Growing cancer incidence has led to increasing demand for chemotherapy to destroy rapidly growing cancer cells in the body. Chemotherapy may lead to the degeneration of motor nerves and peripheral sensory. It has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. Some chemotherapy drugs may cause peripheral neuropathy, which is resulting in the demand for peripheral neuropathy treatment in which analgesics, antidepressants, or anticonvulsants, as well as topical numbing agents including lidocaine, are often used for the management of pain. Additionally, opioids may be used in cases that involve extreme pain. 

Browse the full report description of "Indian peripheral neuropathy treatment Market Size, Share & Trends Analysis Report, By Type (Antidepressants, Pain Relievers, Antiseizure, and Others), By Application (Diabetes, Chemotherapy-Induced, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/indian-peripheral-neuropathy-treatment-market

Scope of the Indian Peripheral Neuropathy Treatment Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type and Application
• Competitive Landscape- Alembic Pharmaceuticals Ltd., Cipla Ltd., Eli Lilly and Co., and Pfizer Inc.

Recent Strategic Initiatives in the Indian Peripheral Neuropathy Treatment Market

• In July 2019, Cipla declared that InvaGen Pharmaceuticals, its subsidiary gained US approval for Pregabalin Capsules, which is intended for neuropathic pain management associated with some illnesses. InvaGen gained approval from the US FDA for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg.
• In July 2019, Alembic Pharmaceuticals declared the US FDA approval for Pregabalin Capsules, indicated for neuropathic pain management associated with some illnesses. This drug is therapeutically similar to the Lyrica Capsules of PF Prism CV. Pregabalin capsule aimed for neuropathic pain management associated with management of postherpetic neuralgia, diabetic peripheral neuropathy, management of neuropathic pain associated with spinal cord injury, adjunctive therapy to treat partial-onset seizures in patients 17 years of age and older, and fibromyalgia management.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19 forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Indian Peripheral Neuropathy Treatment Market-Segmentation

By Type

• Antidepressants
• Pain Relievers
• Antiseizure 
• Others 

By Application

• Diabetes 
• Chemotherapy-Induced 
• Others

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/indian-peripheral-neuropathy-treatment-market